ISCT 2017 Annual Meeting

2017 marks the 25th anniversary of the International Society for Cellular Therapy. This years annual meeting is being held in London from 3 - 6 May 2017.

Established in 1992, ISCT is a global society of clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives worldwide.

This years venue, ExCeL London, is their largest ever, with plenty of networking space, and they expect the meeting and the attendees to reflect the diversity and excitement of the host city.

Cell and Gene Therapy Catapult will be attending the event, you can come and visit us at booth 707. We are also taking part in the following sessions:

Dr Jacqueline Barry, Chief Clinical Officer
Industrializing the Vein to Vein Supply Chain
Thursday 4 May, 15:30 - 17:00
Platinum room 4

Building on the previous discussions this session will investigate the impact of increasing numbers of therapies becoming approved, with wider numbers of patients being treated, how the inbound (raw materials, inc donor cells) and outbound (drug substance) supply chains need to evolve to ensure that they don’t become a cost or physical barrier to adoption/sales/patient treatment. This session needs to link with the subsequent one and focus on the “out of factory” optimisation that is required to create a viable logistics infrastructure at industrial scale.

Dr Fungayi Chidothe, Senior Manager - Strategy and Planning
Industrialising talent management
Saturday 6 May, 07:30-08:30
Platinum room 4

The ability to attract and retain talent is fundamental to the success of any business. The strategies employed to build a high-performing team in a cell therapy context – from Board level recruitment through to skilled technician – will be described. There will also be the opportunity to update on the findings of the Advanced Manufacturing Taskforce Skills sub-team.

Matthew Durdy, Chief Business Officer
Industrializing the CGT Business Model
Friday 5 May, 10:45-12:15
Platinum room 4

Industrialising the CGT business model depends on market demand and adoption. However, with highly complex regulatory, manufacturing, quality control, cold chain distribution, and patient administration, COG and pricing are higher than typical drugs. This dynamic presents potential reimbursement and market entry challenges for commercializing cell and gene therapy products. Therefore, for industrializing CGT it is important to think about the commerical model early in development. Market access for patients must be a focus in the lab, through manufacturing process development, clinical development and at commercial launch, to ensure that these innovative products are reimbursed and adopted by physicians for their intended patients. What are the key considerations during development and key disciplines at launch for successful commercialization?

Dr Damian Marshall, Head of Analytical Development
Overcoming Analytical Challenges for Characterization of Advanced Therapies
Saturday 6 May, 07:30-08-30
Platinum room 2

This session will look at the range of analytical challenges faced by cell therapy developers, highlighting common problems, skills requirements and how new technologies can be used to characterise complex products.

Dr Stephen Ward, Chief Operating Officer
Process and product approach to automation
Saturday 6 May, 15:30-16:30
Platinum room 4

Cost of Goods and manufacturability are critical elements in the success of the therapy. Achieving a reasonable CoGs for cell therapy is challenging and has to be integrated during the development stages to insure automation and process optimization. The session will focus on strategy to introduce and ensure manufacturability during development and will provide case studies and methodology examples. The session will end with a panel discussion with the PPD subcommittee experts.

The following posters will also be on display:

Development of a Novel Potency Assay to Quantify Immune Cell-Mediated Cancer Cell Killing    
Alexander Chan

Optimisation and Qualification of an RT-qPCR assay for miRNA detection in exosomes derived from proliferating and differentiating CTX cells    
Andrea Keogh

Developing integrated single-use upstream and downstream platform processing options for allogeneic cell therapy applications: linking the stirred tank bioreactor to the TFF    
Daria Popova

Transfer and optimisation of ATMP manufacturing    
Julie Kerby

A strategy for robust implementation of process analytical technologies to ensure controlled cell therapy manufacture    
Marc-Olivier Baradez

Characterisation of a synamic modular automated system for the scale up of allogeneic and autologous cell therapy products    
Michael Delahaye

A semi-automated cost-efficient process for the closed expansion and harvest of pluripotent stem cells using a hollow fibre bioreactor and continuous centrifugation    
Zahid Hasan

CFD Simulation of Small-Scale Single-use Stirred Tank Bioreactors; Comparisons and Perspectives    
Nick Gaddum

Development of cost efficient platforms for the industrial manufacture of pluripotent stem cell-derived products for cell therapy: cell expansion is the starting point    
Ricardo Baptista

Find out more

Discover who we are